• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy

Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy

by Elena Iemma | Dec 9, 2021

Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease

Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease

by Elena Iemma | Jun 22, 2021

Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs

Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs

by Elena Iemma | Apr 20, 2021

Immunome-derived Epitope-driven Vaccines (ID-EDV) Protect against Viral or Bacterial Challenge in Humanized Mice

Immunome-derived Epitope-driven Vaccines (ID-EDV) Protect against Viral or Bacterial Challenge in Humanized Mice

by Annie De Groot | Mar 25, 2020

Moise et al. Immunome-derived Epitope-driven Vaccines (ID-EDV) Protect against Viral or Bacterial Challenge in Humanized Mice _
In silico identification and modification of T cell epitopes in pertussis antigens associated with tolerance

In silico identification and modification of T cell epitopes in pertussis antigens associated with tolerance

by Annie De Groot | Jan 22, 2020

Kruiswijk et al 2020 – In silico identification and modification of T cell epitopes in pertussis antigens associated with tolerance

Recent Posts

  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
  • Smarter Tools, Safer Therapies: Supporting the FDA’s Roadmap with in silico Immunogenicity Assessment
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.